We Are Still in a COVID Wave
The Omicron subvariants BA.5 and BA.4 are still causing a large wave of infections throughout the United States. They are the most infectious COVID variants to date.
Please continue to mask in all shared spaces of the GW MFA, including nonclinical spaces.
- Please avoid eating indoors in groups given the high risk of transmission posed by this subvariant.
Following are recommended therapies for early treatment of COVID-19 among high-risk individuals:
Nirmatrelvir/ritonavir (PAXLOVID) and the monoclonal antibody (BEBLETOVIMAB) continue to have efficacy for all currently circulating Omicron subvariants. Early treatment can substantially reduce the risk of progression to severe disease.
Paxlovid (within five days of symptom onset): Authorized for treating high-risk outpatients with mild to moderate COVID. It is active against all variants and subvariants to date and reduced the risk of severe COVID by 89%. Please refer to this guidance for criteria and details. Please look up potential drug-drug interactions here. Paxlovid is available at the MFA Pharmacy and other pharmacies. Please indicate the patient’s renal function when prescribing Paxlovid. This drug can now be prescribed by pharmacists as well as other licensed practitioners.
Bebletovimab (within seven days of symptom onset): This therapeutic monoclonal antibody is available at GWUH in limited quantity. It is authorized for high-risk patients with mild to moderate COVID who meet the criteria outlined in these guidelines.